Ampyra (Dalfampridine) for Multiple Sclerosis | MyMSTeam

Connect with others who understand.

sign up Log in
Resources
About MyMSTeam
Powered By

Overview
Ampyra is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to improve walking speed in adults with all types of multiple sclerosis (MS). It is the first drug that has been approved for this purpose. Ampyra may also be referred to by its drug name, dalfampridine.

Ampyra may not be appropriate for people with kidney problems or a history of seizures. It is unknown whether Ampyra is safe to take during pregnancy or breastfeeding.

Ampyra is a potassium channel blocker. Ampyra is believed to work by increasing the conductivity of nerves. In other words, it improves communication routes between your brain and your body that are damaged by demyelination in MS.

How do I take it?
Ampyra comes in extended-release tablets. The maximum dosage of Ampyra is one 10 mg tablet twice daily, 12 hours apart. Always follow your doctor’s instructions exactly when taking Ampyra.

Side effects
Common side effects of Ampyra include urinary tract infection, insomnia, dizziness, headache, nausea, fatigue, back pain, balance disorder, multiple sclerosis relapse, infection of the upper respiratory tract, and constipation.

Ampyra can cause seizures in anyone. There is an increased likelihood of seizures if you are taking higher doses of Ampyra; if you crush or break the tablet; if you take doses too close together; if you have had a seizure before; or if you have kidney problems. Discontinue taking Ampyra and notify your doctor if you experience a seizure. Ampyra can also cause allergic reactions. Get medical help immediately if you experience difficulty breathing or swelling in the face, throat, eyes, lips or tongue.

For more information, please visit:

Ampyra — Acorda Therapeutics
https://ampyra.com

Ampyra — National MS Society
https://www.nationalmssociety.org/Treating-MS/M...

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of use and Privacy policy.
Already a Member? Log in